MétaCan
Menu
Back to cohort
Record W2057360831 · doi:10.1158/1535-7163.targ-11-c25

Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).

2011· article· en· W2057360831 on OpenAlexaff
Suzanne Richter, Ben Tran, Krupa Patel, Alberto Ocaña, Lisa Wang, Christine Haines, Melanie Recel, Eric X. Chen, Ian F. Tannock, Lillian L. Siu, Philippe L. Bédard

Bibliographic record

VenueMolecular Cancer Therapeutics · 2011
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicATP Synthase and ATPases Research
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineNeutropeniaMucositisFebrile neutropeniaEpirubicinCancerPharmacologyDoxorubicinCardiotoxicityPharmacokineticsAnthracyclineToxicityInternal medicineChemotherapyGastroenterologyBreast cancer

Abstract

fetched live from OpenAlex

Abstract Background: Chemoresistance may occur through acidification of the tumor microenvironment, impaired uptake and the inhibition of autophagy. PTP is a proton pump inhibitor that reduces gastric acidification in peptic ulcer disease. Our preclinical studies demonstrate that high dose intravenous (IV) PTP increases the nuclear localization and anti-tumor activity of DOX in xenografts, suggesting It may represent a novel approach to increasing tumor sensitivity. The primary objective of this phase 1 trial is to evaluate the recommended phase II dose and safety profile of IV PTP in combination with DOX; secondary objectives are to assess the preliminary anti-tumor activity, evaluate pharmacokinetics (PK) and to evaluate the influence of PTP on DOX distribution in tumor tissue. Methods: Patients are eligible with advanced solid tumors with no further standard treatment options, an ejection fraction 50% and prior exposure of 240 mg/m2 DOX or 300 mg/m2 of epirubicin. Treatment is with DOX 60mg/m2 with PTP at 4 predetermined dose levels on a 3 weekly schedule using a 3+3 design. The dose limiting toxicity (DLT) period is 21 days. A DLT is defined as CTCAE v4 grade (g) 4 thrombocytopenia; g4 neutropenia 7 days; g3 febrile neutropenia; g3 infection with g3 neutropenia 7 days; g3 nonhematologic toxicities; and any toxicity resulting in the inability to administer day 1 of a planned cycle within 14 days. Study assessments include weekly hematology and biochemistry (C1, 2) then q3wkly (C3); clinical assessment q3wkly, CT imaging q9wkly and cardiac function q6wkly. Plasma samples for DOX PK analysis are collected post dose at 0, 1, 2, 4, 8, 24, 48 and 72 hours. Results: As of August 2011, a total of 9 patients have been treated at 80 (DL1), 160 (DL2) and 240 mg (DL3) PTP dose levels. The median age was 61 years (42–73), ECOG PS 1, median treatment time 3 cycles (1,8). Treatment related g 3 toxicities are shown (Table 1). Partial response by RECIST v1.1 was achieved in 1 pt and stable disease in 4 pts. Preliminary data demonstrated no effect of pantoprazole on DOX PKs. Mean Cmax at 240mg PTP correlated to levels observed to enhance chemotherapy in our mice xenografts. Conclusions: The combination is well tolerated and adverse events were consistent with toxicity profile for DOX alone. Objective antitumor activity was seen. Dose escalation is ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C25.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.110
Threshold uncertainty score0.771

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.066
GPT teacher head0.398
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicATP Synthase and ATPases ResearchFrench-language works237,207